Floatz logo

GADOLINIC ACID, (N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)-3-(4-ETHOXYPHENYL)PROPYL)-N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)ETHYL)GLYCINATO(5-)-.KAPPA.N,.KAPPA.O)-

Liver Dysfunction

Seoul National University HospitalSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Liver Dysfunction cohort.

Asset / SponsorPhaseRating
BISMUTH SUBCITRATE
Tehran University of Medical Sciences
Phase 2B
Omeprazole
Tehran University of Medical Sciences
Phase 2B
Amoxicillin
Tehran University of Medical Sciences
Phase 2B
Azithromycin
Tehran University of Medical Sciences
Phase 2B
RAMIFENTANYL
Tang-Du Hospital
Phase 2CCC

View all 18 →

Same molecule, other indications

GADOLINIC ACID, (N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)-3-(4-ETHOXYPHENYL)PROPYL)-N-(2-(BIS((CARBOXY-.KAPPA.O)METHYL)AMINO-.KAPPA.N)ETHYL)GLYCINATO(5-)-.KAPPA.N,.KAPPA.O)- is also rated in:

Carcinoma, HepatocellularDormant
BB
Indicative ·
65 / 100
View asset →
CirrhosisDormant
B
Indicative ·
62 / 100
View asset →
hepatocellular carcinomaDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →